非顺铂同期药物联合根治性放疗治疗局部晚期头颈癌:随机研究网状Meta分析
该网状Meta分析纳入29项随机对照试验、18种治疗方案,评估非顺铂同期药物联合根治性放疗对局部晚期头颈鳞癌的疗效与安全性。三种含顺铂方案在总生存上排名前三;不能耐受顺铂者中,卡铂、丝裂霉素C方案及每周多西他赛联合放疗为可行替代,西妥昔单抗和免疫检查点抑制剂联合放疗排名最低。
要点
- 三种含顺铂方案联合放疗在总生存上排名前三,顺铂仍为标准治疗。
- 不能耐受顺铂者,卡铂、丝裂霉素C方案及每周多西他赛联合放疗为可行替代。
- 西妥昔单抗和免疫检查点抑制剂联合放疗在所有评估结局中排名最低。
核心结论
- 顺铂仍为标准治疗,但卡铂、丝裂霉素C方案及每周多西他赛联合放疗可作为不能耐受顺铂的III-IV期头颈鳞癌患者的同期替代方案。
研究设计与样本
- 网状Meta分析纳入29项随机对照试验,评估18种治疗方案,比较根治性放疗联合非顺铂系统治疗与放疗联合或不联合顺铂。
主要发现
- 三种含顺铂方案联合放疗在总生存上排名前三,每周多西他赛联合放疗紧随其后。
- 无进展生存排名前两位为丝裂霉素C方案联合放疗和甲氨蝶呤联合放疗,SUCRA分别为83%和79%。
- 局部区域控制排名前两位为丝裂霉素C方案联合放疗和每周多西他赛联合放疗,SUCRA分别为97%和93%。
- 西妥昔单抗和免疫检查点抑制剂联合放疗在所有评估结局中排名最低。
关键数值与推荐
- 无进展生存SUCRA:丝裂霉素C方案联合放疗83%,甲氨蝶呤联合放疗79%。
- 局部区域控制SUCRA:丝裂霉素C方案联合放疗97%,每周多西他赛联合放疗93%。
临床怎么用
- 对不能耐受顺铂的III-IV期头颈鳞癌患者,可考虑卡铂、丝裂霉素C方案或每周多西他赛联合根治性放疗作为同期替代。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) poses a significant clinical challenge, particularly in its locally advanced stages. Cisplatin-based, definitive, chemoradiotherapy (CRT) is recognized as the preferred treatment strategy, providing substantial survival benefits and currently achieving the best locoregional control (LRC). However, the toxicity profile of cisplatin, which includes nephrotoxicity, neurotoxicity, and ototoxicity, restricts its application in patients with comorbidities or those of advanced age. Emerging alternatives such as carboplatin, taxanes, cetuximab, and immune checkpoint inhibitors (ICIs) are gaining attention. This study undertakes a network meta-analysis (NMA) to assess the effectiveness and safety of these agents in conjunction with definitive RT. METHODS: The inclusion criteria targeted definitive RT in conjunction with non-cisplatin systemic therapies, compared to RT with or without cisplatin in adult HNSCC patients. The outcomes evaluated included overall survival (OS), progression-free survival (PFS), and locoregional control (LRC). Statistical methodologies, including the Surface Under the Cumulative Ranking Curve (SUCRA), were employed to rank the treatment protocols. RESULTS: The analysis incorporated 29 randomized controlled trials assessing 18 treatment modalities. Three cisplatin-based regimens combined with RT consistently demonstrated superior efficacy in OS, ranking as the 3 most effective option for OS, followed by weekly docetaxel combined with RT. Non-cisplatin alternatives such as mitomycin C-based regimens + RT, and methotrexate + RT, demonstrated promising efficacy. For PFS, they ranked first and second, with SUCRA scores of 83 % and 79 %, respectively. Regarding LRC, mitomycin C-based regimens + RT and weekly docetaxel + RT emerged as the top two options, achieving SUCRA scores of 97 % and 93 %, respectively. Cetuximab and ICIs combined with RT ranked lowest across all assessed outcomes. CONCLUSION: While cisplatin remains the standard of care, carboplatin, mitomycin C-based, and weekly docetaxel + RT regimens present viable alternatives as concurrent agents during RT for patients with stage III-IV HNSCC who are not eligible for cisplatin. It is imperative to develop tailored treatment strategies to enhance clinical outcomes.
引用
- Petrelli F, Trevisan F, Nardone M, et al. Non-cisplatin concurrent agents plus definitive radiotherapy for locally advanced head and neck cancer: A network meta-analysis of randomized studies. Radiother Oncol. 2025. PMID: 40669610. doi:10.1016/j.radonc.2025.111033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。